Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine for Rett can be all in-house.

I would not be surprised if Anavex goes it alone on all the rare orphan disease, such as Fragile X and FTD.

Actually, there is no reason whatsoever that the Rett market can’t be serviced entirely in-house, by Anavex alone. No need for an expensive mass of field reps making appointments with physicians, trying to get them to prescribe the drug. All of the required info will be on the drug info sheet and on professional Rett treatment websites. Once approved, every mother with a Rett daughter, and every Rett-attending physician will learn of drug. Blarcamesine will be the SOC (standard of care) drug. Merely a matter of the writing of a prescription. That prescription at any drug store will allow the pharmacy to contact its supply service for delivery. In a day or two it can be picked up and administered to the Rett patient. Nothing complicated about any of this at all. Again, no need for a mass of expensive field reps (drug sales people) to get physicians to prescribe, or patients to take the drug.